GILD · Earnings call · 2026Q3T · Full report
Strategic Initiatives
GILEAD SCIENCES, INC. · 2026-10-29 · Importance 24 · Surprise 24 · In source text
Gilead described an eight-year strategy to diversify its portfolio across HIV treatment and PrEP, oncology, and inflammation. Management said the company is pursuing differentiated mechanisms in oncology, cell therapy, and autoimmune disease, with the aim of addressing efficacy barriers and unmet medical needs. The strategy also includes expanding longer-acting HIV treatment and prevention options.
Key facts
- Gilead reported a $1.1 billion headwind from Medicare Part D redesign in 2025 and a greater than $500 million headwind from the Affordable Care Act and other government policies in 2026.
- Over the past 8 years or so, Gilead's strategy has been to diversify its portfolio across different areas.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | — | Gilead reported a $1.1 billion headwind from Medicare Part D redesign in 2025 and a greater than $500 million headwind from the Affordable… |